Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BIIO Stock Summary
In the News
Bionovate applies to list on NASDAQ
CHAM, Switzerland, May 03, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announced that it has submitted a formal application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”). NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world's best technology companies.
Bionovate announces to reduce shares
CHAM, Switzerland, April 30, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announces the cancellation and return to treasury of 25,000,000 common shares of the company's stock. The stock transactions will soon be represented in reports filed with the United States Securities and Exchange Commission (“SEC”).
Bionovate Technologies Stock Is Estimated To Be
The stock of Bionovate Technologies (OTCPK:BIIO, 30-year Financials) shows every sign of being , according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.
Bionovate Supports Startups in the Digital Health Markets
CHAM, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp (OTCMKT: BIIO) (“Bionovate”), is currently in the process of compiling a shortlist for potential investments in start-ups in the digital healthcare markets, as announced. The COVID-19 pandemic has accelerated the digital transformation of the healthcare market and launched numerous innovative start-ups.
Bionovate Announces Return of Shares to Treasury
CHAM, Switzerland, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on the Nasdaq OTC (OTCPK:BIIO), announces the cancellation and return to treasury of 13,820,000 common shares of the company's stock. The stock transactions will soon be represented in reports filed with the United States Securities and Exchange Commission (“SEC”).
Bionovate seeks to invest in Health and Life Care Startups
CHAM, Switzerland, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on the Nasdaq OTC (OTCPK:BIIO), plans to strategically invest in startups in Europe in the health and life care sector and focus its investments strategy towards on-demand healthcare services. The company is in the process of building a shortlist of startups which have the potential of disrupting their respective industry.
Bionovate realigns its strategy: from Quantify Yourself to Know Yourself
CHAM, Switzerland, Nov. 27, 2020 (GLOBE NEWSWIRE) -- The medical device company Bionovate Technologies Corp adopts a strategic reorientation under new management. Aleksandar Vucak will realign the company as CEO after taking over the majority of the shares of the company, traded on the Nasdaq OTC (OTCPK:BIIO).
BIIO Financial details
BIIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.34 | -0.01 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -2.13 | -0.02 | -0.01 | 0 | 0 | |
Tangible book value per share | -2.13 | -0.02 | -0.01 | 0 | 0 | |
Share holders equity per share | -2.13 | -0.02 | -0.01 | 0 | 0 | |
Interest debt per share | 2.42 | 0.01 | 0.01 | 0 | 0 | |
Market cap | 1.07M | 25M | 42.84M | 0 | 0 | |
Enterprise value | 1.3M | 25.18M | 43.08M | 0 | 0 | |
P/E ratio | -5.14 | -118.39 | -255.79 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.68K | 245.06K | -181.53K | 0 | 0 | |
PFCF ratio | -3.68K | 245.06K | -181.53K | 0 | 0 | |
P/B Ratio | -3.24 | -63.01 | -85.13 | 0 | 0 | |
PTB ratio | -3.24 | -63.01 | -85.13 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -22.99 | -761.79 | -949.46 | 0 | 0 | |
EV to operating cash flow | -4.45K | 246.87K | -182.53K | 0 | 0 | |
EV to free cash flow | -4.45K | 246.87K | -182.53K | 0 | 0 | |
Earnings yield | -0.19 | -0.01 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | -0.68 | -0.47 | -0.47 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -3.97 | -5.61 | -5.23 | 0 | 0 | |
Current ratio | 0 | 0 | 0 | 0 | 0 | |
Interest coverage | -0.37 | -0.37 | -0.74 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 8.03 | 0.05 | 0.03 | 0 | 0 | |
ROIC | 0.53 | 0.27 | 0.27 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | -2.13 | -0.02 | -0.01 | 0 | 0 | |
Working capital | -332.29K | -396.67K | -503.21K | 0 | 0 | |
Tangible asset value | -332.29K | -396.67K | -503.21K | 0 | 0 | |
Net current asset value | -332.29K | -396.67K | -503.21K | 0 | 0 | |
Invested capital | -0.68 | -0.47 | -0.47 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 74.05K | 66.65K | 28.83K | 15.98K | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.63 | 0.53 | 0.33 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q1
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0 | 0 | 0 | 0 | 0 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 0 | 0 | 0 | |
Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 0 | 0 | 0 | 0 | 0 | |
Enterprise value | 0 | 0 | 0 | 0 | 0 | |
P/E ratio | 0 | 0 | 0 | 0 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 0 | 0 | 0 | 0 | |
PTB ratio | 0 | 0 | 0 | 0 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0 | 0 | 0 | 0 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0 | 0 | 0 | 0 | 0 | |
Current ratio | 0 | 0 | 0 | 0 | 0 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 0 | 0 | 0 | |
ROIC | 0 | 0 | 0 | 0 | 0 | |
Return on tangible assets | 0 | 0 | 0 | 0 | 0 | |
Graham Net | 0 | 0 | 0 | 0 | 0 | |
Working capital | 0 | 0 | 0 | 0 | 0 | |
Tangible asset value | 0 | 0 | 0 | 0 | 0 | |
Net current asset value | 0 | 0 | 0 | 0 | 0 | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
BIIO Frequently Asked Questions
What is Bionovate Technologies Corp. stock symbol ?
Bionovate Technologies Corp. is a CH stock and trading under the symbol BIIO
What is Bionovate Technologies Corp. stock quote today ?
Bionovate Technologies Corp. stock price is $0.0001 today.
Is Bionovate Technologies Corp. stock public?
Yes, Bionovate Technologies Corp. is a publicly traded company.